Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study

Autor: Jennifer Hammond, Michael Benigno, Nataly Bleibdrey, Wajeeha Ansari, Jennifer L. Nguyen
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Drugs - Real World Outcomes, Vol 11, Iss 2, Pp 273-283 (2024)
Druh dokumentu: article
ISSN: 2199-1154
2198-9788
DOI: 10.1007/s40801-024-00422-5
Popis: Abstract Background and Objective Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia results in substantial morbidity and mortality. As current treatments often lead to unsatisfactory outcomes, evidence guiding alternative treatment options is needed. This study evaluated real-world clinical outcomes of ceftaroline fosamil for the treatment of MRSA bacteremia. Methods This retrospective study included adults hospitalized with MRSA bacteremia between 2011 and 2019. Patients were classified according to treatment with ceftaroline fosamil (ceftaroline), vancomycin, or daptomycin: Group 1, ceftaroline; Group 2, vancomycin or daptomycin (without ceftaroline); Group 3, combination therapy with ≥ 2 of these three agents. Clinical outcomes were compared using propensity-score-adjusted odds ratios (ORs) from logistic regression models. Results Overall, 24,479 patients were included (Group 1, n = 532; Group 2, n = 21,555; Group 3, n = 2392). Mean age was 59.6, 60.8, and 57.4 years in Groups 1, 2, and 3, respectively. Mean post-index treatment length of stay was 8.8, 8.8, and 8.0 days, respectively. The most frequent line of therapy was ceftaroline first-line (42.1%), vancomycin or daptomycin first-line (95.4%), and combination therapy third-line or later (67.8%) in Groups 1, 2, and 3, respectively. Compared with Group 2, Groups 1 and 3 had similar favorable clinical responses {odds ratio [OR] = 1.18 [95% confidence interval (CI) 0.98–1.44], p = 0.08; OR = 1.20 [95% CI 0.97–1.47], p = 0.09, respectively} and were less likely to switch treatment (both p
Databáze: Directory of Open Access Journals
Externí odkaz: